- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$5.38 BnMarket Estimate, 2026
$5.96 BnMarket Forecast, 2034
$13.65 BnCAGR, 2026–2034
10.9%Executive Summary: North America Cancer Biomarkers Market
- Market Scope: Comprehensive North American cancer biomarkers market analysis covering disease indications, service types, application workflows, biomarker classifications, and regional landscape frameworks across the U.S. and Canada.
- Market Valuation: Valued at USD 5.38 billion (2025), estimated at USD 5.96 billion in 2026, and projected to reach USD 13.65 billion by 2034, registering a robust CAGR of 10.90% (2026–2034).
- Primary Growth Drivers: Rising cancer incidence due to tobacco consumption, unhealthy dietary habits, UV exposure, genetic and metabolic mutations, hormonal imbalances, growing demand for early diagnostics, an expanding geriatric population, technological advancements, data augmentation, and increased research investments.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment (2025 Position) | Fastest-Growing Segment |
|---|---|---|
| By Disease | Breast & Lung Cancer (leading high incidence rates and extensive clinical screening populations) | Prostate & Colorectal Cancer Applications |
| By Services | Testing Services (anchored by routine diagnostic screening and clinical workflows) | Biomarkers Validation & Assay Development |
| By Application | Disease Diagnosis (capturing primary clinical utility for early tumor detection) | Drug Discovery, Development & Molecular Diagnostics |
| By Type | Genetic Biomarkers (dominant share due to widespread genomic profiling and precision oncology) | Protein Biomarkers |
| By Region / Country | The United States (dominates North America driven by high R&D investments and major research bodies like the NCI) | Canada (projected to grow at a steady 11.4% CAGR supported by an aging demographic and targeted clinical studies) |
Major Market Players & Market Structure
Market Structure: Highly specialized and competitive oncology diagnostics landscape balancing high costs, complex reimbursement frameworks, and strict administrative regulations with expanding opportunities in companion diagnostics and personalized medicine.
Key Companies: Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A, Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc, and Aureon Laboratories Inc.
North America Cancer Biomarkers Market Size
The North America Cancer Biomarkers Market is projected to grow from USD 5.38 billion in 2025 to USD 5.96 billion in 2026 and reach USD 13.65 billion by 2034, registering a CAGR of 10.90% during the forecast period from 2026 to 2034.
The significant factors that are fuelling the growth of cancer biomarker are the occurrence of cancer due to increasing rate in consumption of tobacco, unhealthy food habits, frequent exposure to UV and sunlight metabolic mutation, genetic mutation and hormonal imbalance, and rise in demand for early diagnosis and rise in the geriatric population.
Growing adoption of biomarkers in drug target developments and surrogate endpoints, increasing focus on research and progress due to advancements of technology, data augmentation, and growing investments also contribute to the growth of the North American cancer biomarkers market.
The factors limiting the cancer biomarkers market's growth are reimbursements and regulations, biomarker techniques are high expensive, reluctance in adopting new technologies, and low detection rate.
Companion diagnostics and personalized medicines are the specialized fields expanding growth opportunities for the cancer biomarkers market. In addition to this, increasing occurrence of breast and prostate cancers, growing investments owing to ease of government regulations and technological advancements, adoption of biomarkers for detecting tumors, drug development and discovery, in cancer therapies for tracking responses are expected to provide lucrative opportunities for the growth of North America Cancer Biomarkers market.
MARKET SEGMENTATION
This research report on the North America Cancer Biomarkers Market segmented and sub-segmented into the following categories
North America Cancer Biomarkers Market - By Disease
-
Prostate Cancer
-
Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Other Cancers
North America Cancer Biomarkers Market - By Services
-
Sample Preparation
-
Assay Development
- Biomarkers Validation
- Testing
North America Cancer Biomarkers Market - By Application
-
Risk Assessment
-
Development of Molecular Diagnostics
- Disease Diagnosis
- Drug Discovery & Development
- Drug Formulation
North America Cancer Biomarkers Market - By Type
-
Protein Biomarkers
-
Genetic Biomarkers
- Other Biomarkers
North America Cancer Biomarkers Market - By Country
-
The United States
-
Canada
- Rest of North America
Regionally
North America accounted for the largest share in the Global Cancer Biomarkers Market.
The U.S. Cancer Biomarkers Market is anticipated to hold the largest share in the North American market as a result of the increasing necessity for investment in research and development, embellishing the constant rate of cancer, augmenting the government assistance for the discovery and advancing of biomarkers and acquiring advanced technologies for biomarkers. One million seven hundred thirty-five thousand three hundred fifty new cancer cases were diagnosed, and 609,640 deaths occurred due to cancer in this country, according to the American Cancer Society in 2018. According to the American Cancer Society's analysis report, nearly 234,030 new lung cancer cases were recorded, and about 154,050deaths occurred due to lung cancer.
The Canadian cancer biomarkers market is next to the U.S., leading the majority share in the North American market. It is expected to grow with a CAGR of 11.4% during the forecast period. Canada has a population of 36 million in 2018, which records for 0.48% of the world's total population. The elder people population anticipates the Canadian market, a large patient pool diagnosed with cancer. Lung cancer is the leading segment that causes more death in Canada. Around 21% of new cancer cases in men are diagnosed with prostate cancer, 58 men will be diagnosed with prostate cancer every day, whereas 11men will be reduced from prostate cancer every day. Out of 2, 1 will have cancer, and out of 4, 1will die due to cancer, which is reported according to the Canadian Cancer Reports.
KEY MARKET PLAYERS
Leading companies operating in the North American Cancer Biomarkers Market profiled in this report are Abbott Laboratories, Agendia Bv, Biocurex Inc, Biomerieux S.A, Biomoda Inc, Astellas Pharma Us Inc, Correlogic Systems Inc, Beckman Coulter Inc, Becton, Dickinson And Company, Clarient Inc, Diadexus Inc, Ambrilia Biopharma, Affymetrix Inc and Aureon Laboratories Inc.